| Increased survival with enzalutamide in prostate cancer after chemotherapy HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R De Wit, ... New England Journal of Medicine 367 (13), 1187-1197, 2012 | 5361 | 2012 |
| Abiraterone and increased survival in metastatic prostate cancer JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ... New England Journal of Medicine 364 (21), 1995-2005, 2011 | 5162 | 2011 |
| Enzalutamide in metastatic prostate cancer before chemotherapy TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... New England Journal of Medicine 371 (5), 424-433, 2014 | 3490 | 2014 |
| Pembrolizumab as second-line therapy for advanced urothelial carcinoma J Bellmunt, R De Wit, DJ Vaughn, Y Fradet, JL Lee, L Fong, NJ Vogelzang, ... New England Journal of Medicine 376 (11), 1015-1026, 2017 | 3384 | 2017 |
| Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial CN Sternberg, ID Davis, J Mardiak, C Szczylik, E Lee, J Wagstaff, ... Journal of clinical oncology 28 (6), 1061-1068, 2010 | 3080 | 2010 |
| Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical … HI Scher, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, ... Journal of clinical oncology 26 (7), 1148-1159, 2008 | 2487 | 2008 |
| Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial M Bolla, L Collette, L Blank, P Warde, JB Dubois, RO Mirimanoff, ... The Lancet 360 (9327), 103-108, 2002 | 2198 | 2002 |
| Pazopanib versus sunitinib in metastatic renal-cell carcinoma RJ Motzer, TE Hutson, D Cella, J Reeves, R Hawkins, J Guo, P Nathan, ... New England Journal of Medicine 369 (8), 722-731, 2013 | 2157 | 2013 |
| Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin M Bolla, D Gonzalez, P Warde, JB Dubois, RO Mirimanoff, G Storme, ... New England Journal of Medicine 337 (5), 295-300, 1997 | 1856 | 1997 |
| Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo … K Fizazi, HI Scher, A Molina, CJ Logothetis, KN Chi, RJ Jones, ... The lancet oncology 13 (10), 983-992, 2012 | 1748 | 2012 |
| Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall … CJ Ryan, MR Smith, K Fizazi, F Saad, PFA Mulders, CN Sternberg, ... The Lancet Oncology 16 (2), 152-160, 2015 | 1628 | 2015 |
| Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ... Journal of Clinical Oncology 34 (12), 1402-1418, 2016 | 1451 | 2016 |
| Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open … A Wang-Gillam, CP Li, G Bodoky, A Dean, YS Shan, G Jameson, ... The Lancet 387 (10018), 545-557, 2016 | 1260 | 2016 |
| Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma T Powles, SH Park, E Voog, C Caserta, BP Valderrama, H Gurney, ... New England Journal of Medicine 383 (13), 1218-1230, 2020 | 1202 | 2020 |
| Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium JL Gabrilove, A Jakubowski, H Scher, C Sternberg, G Wong, J Grous, ... New England Journal of Medicine 318 (22), 1414-1422, 1988 | 1154 | 1988 |
| Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer M Hussain, K Fizazi, F Saad, P Rathenborg, N Shore, U Ferreira, ... New England Journal of Medicine 378 (26), 2465-2474, 2018 | 1141 | 2018 |
| External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study M Bolla, G Van Tienhoven, P Warde, JB Dubois, RO Mirimanoff, G Storme, ... The lancet oncology 11 (11), 1066-1073, 2010 | 1107 | 2010 |
| Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial TK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ... The lancet oncology 17 (7), 917-927, 2016 | 1094 | 2016 |
| Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) M Bolla, H van Poppel, B Tombal, K Vekemans, L Da Pozzo, ... The Lancet 380 (9858), 2018-2027, 2012 | 931 | 2012 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 884* | 2018 |
